Today my guests are Dr Meriem Sefta, Chief Diagnostics Officer at Owkin, and Amanda Coble, Senior Director of Product at Proscia.

What we discuss with Amanda and Dr Sefta:

• The history of Owkin
• Founding vision and early challenges
• Deep learning in pathology
• Mission and Precision Oncology
• Digital pathology and AI integration
• Biomarker screening products like MSIntuit CRC
• Outcome prediction solutions like RlapsRisk BC
• Partnership with Proscia
• The future of pathology with AI
• Interoperability and collaboration

Disclaimer:

MSIntuit CRC, BRCAura BC, and RlapsRisk BC are under development and not for clinical use. They are not FDA cleared or approved in the USA. BRCAura BC and RlapsRisk BC are developed within the PortrAIt consortium, a french consortium financed by the government within the framework of France 2030 and by the European Union - Next Generation EU within the framework of the France Relance Plan.

Owkin interoperability with Proscia's software is for Research Use Only. Not for use in diagnostic procedures.

Links for this episode:

The Path to PathA

Pathologists' Assistant Shadowing Network

Health Podcast Network

LabVine Learning

Dress A Med scrubs

Digital Pathology Club

Owkin And Proscia Expand Access To AI Pre-Screening For Colorectal Cancer Patients

Owkin

Proscia

People of Pathology Podcast:

Twitter

Instagram